Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To study the effect of growth hormone (GH) treatment on ovarian and uterine morphology and function in short, prepubertal small-for-gestational-age (SGA) girls.

Who Took Part

The study group was 18 girls.

The age groups tagged for this paper are young children and children, women only.

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A subgroup of 18 Danish girls born SGA included in North European SGA Study (NESGAS).

What Was Measured

The subject headings attached to it are Anti-Mullerian Hormone, Body Height, Human Growth Hormone, Infant, Small for Gestational Age, Insulin-Like Growth Factor I, Ovary and Sexual Maturation.

Author keywords: Growth hormone treatment and ovarian function.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Fertility and sterility), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.